An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2012
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 22 Dec 2011 Actual patient no 6 added as reported by ClinicalTrials.gov.
- 05 Jul 2011 Actual end date changed from Sep 2009 to May 2011 as reported by ClinicalTrials.gov.
- 07 Nov 2009 Actual initiation date changed from May 2009 to Mar 2009 as reported by ClinicalTrials.gov.